Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
| ▸ | MAOB | P27338 | 8/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15458939 | 0.92 | ALDH1A1 (0.68) | ALDH1A1MAPK1MAOBCYP3A4MAOA | |
| SCHEMBL18415547 | 0.90 | ALDH1A1 (0.71) | ALDH1A1MAPK1MAOBMAOANPC1 | |
| SCHEMBL7294658 | 0.88 | ALDH1A1 (1.00) | ALDH1A1MAPK1MAOBCYP3A4MAOA | |
| SCHEMBL19032000 | 0.88 | ALDH1A1 (0.69) | ALDH1A1MAPK1MAOBMAOANPC1 | |
| SCHEMBL14743537 | 0.88 | ALDH1A1 (0.69) | ALDH1A1MAPK1MAOBCYP3A4MAOA | |
| SCHEMBL257873 | 0.88 | ALDH1A1 (0.69) | ALDH1A1MAPK1MAOBNPC1RAB9A | |
| SCHEMBL921951 | 0.87 | ALDH1A1 (0.67) | ALDH1A1MAPK1MAOBCYP3A4MAOA | |
| SCHEMBL22162810 | 0.86 | MEN1 (0.64) | ALDH1A1MAPK1MAOBCYP3A4MAOA | |
| SCHEMBL16628033 | 0.84 | ALDH1A1 (0.63) | ALDH1A1MAPK1MAOBNPC1RAB9A | |
| SCHEMBL9505708 | 0.84 | ALDH1A1 (0.63) | ALDH1A1MAPK1MAOBCYP3A4MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113683492-A | Preparation method of 3-phenoxybromopropane or analogue thereof | 常熟理工学院 | 2021-11-23 | — | — | CN | disclosed |
| EP-1102751-A4 | NOVEL BI- AND TRI-CYCLIC AZA COMPOUNDS AND THEIR USES | UNIV GEORGETOWN (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040147754-A1 | Novel process | SMITHKLINE BEECHAM PLC | 2004-07-29 | — | — | US | disclosed |
| US-6716985-B2 | ALCOHOLISM, PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-04-06 | — | — | US | disclosed |
| US-6489347-B1 | NOVEL INTERMEDIATE CARBOXALDEHYDES FOR PHARMACEUTICAL PRODUCTS WITH ANTIDEPRESSANT AND ANTI-PARKINSON PROPERTIES | SMITHKLINE BEECHAM PLC (GB) | 2002-12-03 | — | — | US | disclosed |
| US-20020133011-A1 | Novel process | SMITHKLINE BEECHAM PLC | 2002-09-19 | — | — | US | disclosed |
| EP-0986389-A4 | NOVEL PROCESS | SMITHKLINE BEECHAM CORP (US) | 2001-09-12 | — | — | EP | disclosed |
| EP-1102751-A1 | NOVEL BI- AND TRI-CYCLIC AZA COMPOUNDS AND THEIR USES | Georgetown University (US) | 2001-05-30 | — | — | EP | disclosed |
| CN-1268889-A | Novel process for obtg. intermediates | SMITHKLINE BEECHAM CORP (US) | 2000-10-04 | — | — | CN | disclosed |
| EP-0986389-A1 | NOVEL PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-2000007994-A1 | NOVEL BI- AND TRI-CYCLIC AZA COMPOUNDS AND THEIR USES | GEORGETOWN UNIVERSITY (US) | 2000-02-17 | — | — | WO | disclosed |
| WO-1998053824-A1 | NOVEL PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133011-A1 | Novel process | HTR1A, HTR4, MAOA | ALDH1A1 900/4885MAPK1 2468/4885MAOB 16/4885 |
| US-20040147754-A1 | Novel process | HTR1A, HTR4, HTR2B | ALDH1A1 1013/4885MAPK1 2149/4885MAOB 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.